Editas Medicine (EDIT) Total Current Liabilities (2015 - 2025)

Editas Medicine (EDIT) has reported Total Current Liabilities for 11 consecutive years, with $46.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Current Liabilities fell 40.12% year-over-year to $46.2 million; the TTM figure through Dec 2025 stood at $46.2 million (down 40.12% YoY), while the FY2025 annual figure was $46.2 million, down 40.12% from the prior year.
• Total Current Liabilities retreated to $46.2 million in Q4 2025 per EDIT's latest filing, from $61.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $77.2 million in Q4 2024 and bottomed at $36.4 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $58.7 million across 5 years, with a median of $60.9 million in 2022.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 44.83% — and 2023, when it surged 56.58%.
• Editas Medicine's Total Current Liabilities stood at $46.9 million in 2021, then gained by 28.21% to $60.1 million in 2022, then climbed by 5.17% to $63.2 million in 2023, then grew by 22.16% to $77.2 million in 2024, then slumped by 40.12% to $46.2 million in 2025.
• Business Quant data shows EDIT's Total Current Liabilities at $46.2 million in Q4 2025, $61.8 million in Q3 2025, and $65.9 million in Q2 2025.